Results demonstrated that with the treatments of AMPK activator, angustoline or (AMPK activator + angustoline), PC (16:0/18:1) was downregulated and LPC (16:0) was upregulated when compared with the control (p < 0.05, Figure 6), validating that angustoline could suppress esophageal tumor through activating AMPK and inhibiting ELAVL1/LPCAT2, which consequently affecting phospholipids remodeling. The gene discussed is PRKAA1; the disease is neoplasm of esophagus.